Biogen
BIIB · NASDAQ · USD · Healthcare
1What is happening
Biogen has fallen 4% since its 6-week high on 28/10/2026. How it continues – phase and signs – you see with a free account.
Free account · 3 stocks and coins a dayfrom the 6-week high-4.0%
Other view · 32 analystsHorizon: 12 months25 Buy · 10 Hold · 1 Sell2Our assessment
No dip28How it continues – phase and signs – you see with a free account.
3Your next step
Marking places no order – it only helps you keep track.
More details · reasons, figures, alerts
How deep is the dip?
- from the 6-week high-4.0%
Highest daily price: $258.78 on 28/10/2026 · reference of the assessment · also the highest of the last 3 months
- from the 52-week high-4.0%
Highest price in 52 weeks: $258.78 (Yahoo)
What analysts expect
Most of the 32 analysts say buy. They look about 12 months ahead – DipCatcher only 14 trading days.
- Buy
- 2569 %
- Hold
- 1028 %
- Sell
- 13 %
Average price target$266.39
$175.00 to $350.00 · today $248.35
$175.00Ø $266.39$350.00
What is a price target?
The price an analyst expects in about 12 months. Estimates are often far apart and change frequently.
Third-party opinion, not an assessment by DipCatcher. Source: public analyst estimates, as of 08/11/2026. Not financial advice.
The company in figures
- Market value
- 36.7 bn $
- All shares together at the current price.
- P/E
- 107.5
- Price divided by earnings per share, last 12 months.
- 52-week range
- $153.77 – $258.78
- Lowest and highest price of the last year.
Catalysts
36 h ago- News, last 10 days
- no recent news
- Next earnings
- —
- Last report
- 28/10/2026 +31.5% vs estimate
Key figures
- Market value
- 36.7 bn $Large cap
- P/E
- 107.5
- Volume today
- 0.9 × Øabout usual
- Beta
- 0.09swings less than the market
- 52-week range
- $153.77 – $258.78price at 90 % of the range
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
- Headquarters:
- Cambridge, United States
- 52-week range:
- $153.77 – $258.78
- Website:
- biogen.com
Trade levels
Why the engine says so
History for this stock or coin
Watch and alert
See which stocks they are
The engine is watching these dips right now. A free account shows the names and opens 3 full analyses a day.
- 3 full analyses a dayWith entry, target, stop and the reasons behind them.
- WatchlistFollow the stocks you care about.
Free, no payment details.
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search
Not investment advice. Investing carries risk up to total loss.